Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Stomach Cancer Drugs Market – Insights
Stomach cancer, is a buildup of abnormal cells that form a mass in part of the stomach. Symptoms of stomach cancer include fatigue, feeling bloated after eating, severe heartburn, severe indigestion, persistent nausea, stomach pain, persistent vomiting, and unintentional weight loss. There are many treatments available for stomach cancer such as targeted drug therapy, chemotherapy, immunotherapy etc. Stomach cancer drugs are also used in combinations to increase their effectiveness to fight stomach cancer. For instance, TPF is a combination of drugs which include Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil, which is used to kill cancer cells in different ways.
The global stomach cancer drugs market size was valued at US$ 4.0 million in 2017, and is expected to witness a CAGR of 5.4% over the forecast period (2018 – 2026).
Global Stomach Cancer Drugs Market Share (%) Analysis, By Therapy Type, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing FDA approvals of biosimilars for treatment of stomach cancer is expected to drive growth of the stomach cancer drugs market
The stomach cancer drugs market revenue is expected to increase, owing to increasing number of FDA approvals for biosimilars. Adoption of biosimilars in last five years is on a high demand because of the comparatively lower price than biologics treatment of stomach cancer. For instance, in 2017 Biocon Ltd., in partnership with Mylan N.V., received FDA approval for Ogivri (trastuzumab) for the treatment of stomach cancer or gastro-esophageal junction adenocarcinoma. Ogivri is the first FDA-approved biosimilar of Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S. Further, In March 2019, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of TRAZIMERA (trastuzumab), a biosimilar of Herceptin (trastuzumab), for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Moreover, the reimbursement policies for stomach cancer drugs are highly contributing to the stomach cancer drugs market growth. There are government and private healthcare policies which reimburse the charges of stomach cancer drugs which also increases the adoption of drugs because of reimbursement policies. For instance, according to Bristol-Meyer Squibb Medicare Part B will reimburse 80% of the price of Opdivo and remaining 20% is patient’s responsibility. Opdivo is under clinical trial in phase 3 for treatment of stomach cancer.
Stomach Cancer Drugs Market - Restraints
The major restraining factors for growth of the stomach cancer drugs market are the serious side effects caused by the drugs. These include nausea and vomiting, loss of appetite and weight loss, fatigue, diarrhoea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (Deep Vein Thrombosis), nervous system damage, and heart damage in patients undergoing treatment for stomach cancer. According to the 2017, report of the American Cancer Society (ACS) on side effects of stomach cancer, chemotherapy drugs such as doxorubicin and epirubicin can cause permanent damage to the heart if used for a long time or in high doses. As per the same source, other drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause major damage to nerves outside the brain and spinal cord.
Stomach Cancer Drugs Market - Regional Insights
On the basis of region, the global stomach cancer drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global stomach cancer drugs market during the forecast period owing to rising number of clinical trials for drug development for treatment of stomach cancer. For instance, Bristol-Myers Squibb in 2016, initiated a clinical study to test combination treatments for stomach cancer. A comparative study between Nivolumab in combination with other therapies and Nivolumab in combination with Ipilimumab to check which therapy is more effective in treating patients with advanced stomach cancer. In February 2019, the study entered in phase 2 and it is estimated to be completed in 2021.
Asia Pacific is expected to foresee a rapid growth in the stomach cancer drugs market, owing to a rise in launch of biosimilars for treating stomach cancer. For instance, in 2018, Dr. Reddy’s Laboratories launched Hervycta trastuzumab (Herceptin biosimilar) in India. Dr. Reddy’s Laboratories who also developed the biosimilar, said that the drug will be sold under the name Hervycta and it will be used in the treatment of metastatic gastric cancer. Biosimilar trastuzumab is Dr. Reddy’s 4th biosimilar to be commercialized in India and in various other emerging markets.
Global Stomach Cancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026
Source: Coherent Market Insights Analysis (2019)
Stomach Cancer Drugs Market - Competitive Landscape
Key players operating in the global stomach cancer drugs market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.